In prostate cancers, hormone-ablation therapy, in most cases, leads to more aggressive androgen-refractory disease which is characterized by overactivated androgen receptor (AR) mediated signaling and accumulation of cells with neuroendocrine characteristics such as elevation of PTHrP (parathyroid hormone-related protein) levels. This evidence concerns the gene PTHLH and Familial prostate cancer.